跳至主要内容
临床试验/ACTRN12620000627954
ACTRN12620000627954招募中4 期

The effect of a GLP-1 agonist in patients with a dual diagnosis of Parkinson's Disease and Type 2 Diabetes Mellitus

St Vincent's Health Network0 个研究点目标入组 12 人开始时间: 2020年5月29日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
45 Years 至 o limit(—)
性别
All

入选标准

  • 1. Diagnosis of Parkinson’s disease meeting UK Brain Bank Criteria
  • 2. Diagnosis of Type 2 Diabetes not receiving GLP-1 agonist therapy
  • 3. HbA1c greater than or equal to 7 %
  • 4. Willingness to give written informed consent and willingness to participate to and comply with the study.
  • 5. Patients with cognitive impairment sufficient to impair capacity to provide informed consent are excluded from the study (MMSE<24)
  • 6. Age >45 years

排除标准

  • 1. Patient incapable of providing informed consent
  • 2. Patients receiving insulin treatment for type 2 diabetes
  • 3. Contraindications to Extended release Exentatide (Bydureon) therapy including: pregnancy, Multiple Endocrine Neoplasia Type 2, Medullary Carcinoma of the thyroid, active Crohn’s disease or Ulcerative colitis, gastritis or severe gastroparesis, pancreatitis and chronic renal impairment with eGFR<30 ml/min

研究者

发起方
St Vincent's Health Network

相似试验